ContentsIssue 145 • August 2024In association withCover StoryLeft in limbo: when pharma halts rare disease researchFeatureCapturing the genAI boom for drug developmentFeatureToo much data: a burden or a blessing?In DepthLeft in limbo: When pharma halts rare disease researchCapturing the genAI boom for drug developmentToo much data: a burden or a blessing?South Korea seeks to accelerate drug reimbursement administration processSponsors must take on FDA’s diversity guidance to improve community trustBriefingNews in NumbersLatest NewsLatest DealsProject UpdatesIn DataM&A activity in the mining industryHiring activity in the mining industry decreasedPatent activity in the mining industry decreasedSentiment in the mining industry increasedThematic TakeCybersecurity in the healthcare sectorPowered by07/26/2024 08:01:35
